Edwards Lifesciences
1,227 hedge funds and large institutions have $58.1B invested in Edwards Lifesciences in 2021 Q3 according to their latest regulatory filings, with 124 funds opening new positions, 440 increasing their positions, 412 reducing their positions, and 68 closing their positions.
82% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 68
24% more funds holding in top 10
Funds holding in top 10: 17 → 21 (+4)
16% more call options, than puts
Call options by funds: $249M | Put options by funds: $214M
10% more capital invested
Capital invested by funds: $53B → $58.1B (+$5.11B)
4% more funds holding
Funds holding: 1,185 → 1,227 (+42)
7% more repeat investments, than reductions
Existing positions increased: 440 | Existing positions reduced: 412
0.1% less ownership
Funds ownership: 82.52% → 82.42% (-0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$147M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$135M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$123M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$114M |
| 5 |
Korea Investment Corp
Seoul,
South Korea
|
+$94.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$201M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$189M |
| 3 |
DCP
D1 Capital Partners
New York
|
-$127M |
| 4 |
KBC Group
Brussels,
Belgium
|
-$121M |
| 5 |
Bank of New York Mellon
New York
|
-$118M |
EW Hedge Fund Activity: Q3 2021 in Review
1,227 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2021, worth a combined $58.1B — up 9.7% from $53B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new EW positions and 68 closed out — a net gain of 56 holders — while 440 added to existing stakes and 412 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $147M. The largest seller was Ameriprise, cutting an estimated $201M.
- 1,227 institutional investors held Edwards Lifesciences (EW) as of Q3 2021, up from 1,185 in Q2 2021.
- Funds reported $58.1B of Edwards Lifesciences stock for Q3 2021, up 9.7% quarter-over-quarter.
- 124 funds opened new Edwards Lifesciences positions in Q3 2021 and 68 closed out, a net change of +56 holders.
- The largest Edwards Lifesciences buyer in Q3 2021 was Two Sigma Advisers, an estimated $147M added.
- The largest Edwards Lifesciences seller in Q3 2021 was Ameriprise, an estimated $201M sold.
Based on aggregated 13F filings for Q3 2021.